SG11201901889QA - An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy - Google Patents
An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathyInfo
- Publication number
- SG11201901889QA SG11201901889QA SG11201901889QA SG11201901889QA SG11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA SG 11201901889Q A SG11201901889Q A SG 11201901889QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- novartis
- basel
- prevention
- oxazine derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/069843 Al 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: A61K 31/5377 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/IB2017/056281 (22) International Filing Date: 11 October 2017 (11.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16193770.1 13 October 2016 (13.10.2016) EP (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: LOPEZ-LOPEZ, Cristina; Novartis Pharma AG, Postfach, 4002 Basel (CH). NEUMANN, Ulf; Novar- tis Pharma AG, Postfach, Novartis Institutes for Biomed. Research, 4002 Basel (CH). SHIMSHEK, Derya; Novartis _ Pharma AG, Postfach, Novartis Institutes for Biomed. Re- search, 4002 Basel (CH). — = (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel = (CH). (81) Designated States (unless otherwise indicated, for every = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, HN, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States indicated, — (84) (unless otherwise for every _ kind ARIPO GH, _ of regional protection available): (BW, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European AT, BE, BG, DE, DK, (AL, CH, CY, CZ, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = TR), OAPI BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (BF, KM, ML, MR, NE, SN, TD, TG). ,- 1 Declarations under Rule 4.17: ..! — as to applicant's entitlement to apply for and be granted a M patent (Rule 4.1700) 71' of Published: Cs — with international search report (Art. 21(3)) 0 00 (54) Title: AN OXAZINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL AMYLOID Il ANGIOPATHY CZ ei (57) : The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising C such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16193770 | 2016-10-13 | ||
PCT/IB2017/056281 WO2018069843A1 (en) | 2016-10-13 | 2017-10-11 | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901889QA true SG11201901889QA (en) | 2019-04-29 |
Family
ID=57133087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901889QA SG11201901889QA (en) | 2016-10-13 | 2017-10-11 | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |
Country Status (18)
Country | Link |
---|---|
US (1) | US10722518B2 (en) |
EP (1) | EP3525793A1 (en) |
JP (1) | JP2019534885A (en) |
KR (1) | KR20190068567A (en) |
CN (1) | CN109789145A (en) |
AU (1) | AU2017342207B2 (en) |
BR (1) | BR112019006591A2 (en) |
CA (1) | CA3035852A1 (en) |
CL (1) | CL2019001007A1 (en) |
IL (1) | IL265579A (en) |
JO (1) | JOP20190081A1 (en) |
MA (1) | MA46519A (en) |
MX (1) | MX2019004342A (en) |
PH (1) | PH12019500464A1 (en) |
RU (1) | RU2019113756A (en) |
SG (1) | SG11201901889QA (en) |
TW (1) | TW201817424A (en) |
WO (1) | WO2018069843A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10779762B2 (en) * | 2015-10-20 | 2020-09-22 | Washington University | MRI method for in vivo detection of amyloid and pathology in the Alzheimer brain |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050215884A1 (en) | 2004-02-27 | 2005-09-29 | Greicius Michael D | Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI |
US9492114B2 (en) | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
AP3807A (en) | 2011-01-13 | 2016-09-30 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
JO3458B1 (en) * | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
JOP20190003A1 (en) | 2016-07-19 | 2019-01-10 | Novartis Ag | An Oxazine Derivative for Use in the Prevention of Alzheimer?s disease in at Risk Patients |
-
2017
- 2017-06-16 JO JOP/2019/0081A patent/JOP20190081A1/en unknown
- 2017-10-11 CA CA3035852A patent/CA3035852A1/en not_active Abandoned
- 2017-10-11 CN CN201780060026.7A patent/CN109789145A/en active Pending
- 2017-10-11 US US15/730,175 patent/US10722518B2/en active Active
- 2017-10-11 TW TW106134647A patent/TW201817424A/en unknown
- 2017-10-11 EP EP17787965.7A patent/EP3525793A1/en not_active Withdrawn
- 2017-10-11 SG SG11201901889QA patent/SG11201901889QA/en unknown
- 2017-10-11 MA MA046519A patent/MA46519A/en unknown
- 2017-10-11 KR KR1020197012852A patent/KR20190068567A/en not_active Application Discontinuation
- 2017-10-11 JP JP2019519407A patent/JP2019534885A/en active Pending
- 2017-10-11 WO PCT/IB2017/056281 patent/WO2018069843A1/en unknown
- 2017-10-11 MX MX2019004342A patent/MX2019004342A/en unknown
- 2017-10-11 BR BR112019006591A patent/BR112019006591A2/en not_active IP Right Cessation
- 2017-10-11 RU RU2019113756A patent/RU2019113756A/en not_active Application Discontinuation
- 2017-10-11 AU AU2017342207A patent/AU2017342207B2/en not_active Ceased
-
2019
- 2019-03-01 PH PH12019500464A patent/PH12019500464A1/en unknown
- 2019-03-24 IL IL265579A patent/IL265579A/en unknown
- 2019-04-12 CL CL2019001007A patent/CL2019001007A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2019113756A3 (en) | 2021-03-05 |
IL265579A (en) | 2019-05-30 |
AU2017342207A1 (en) | 2019-03-21 |
WO2018069843A1 (en) | 2018-04-19 |
EP3525793A1 (en) | 2019-08-21 |
CL2019001007A1 (en) | 2019-06-21 |
MA46519A (en) | 2019-08-21 |
BR112019006591A2 (en) | 2019-07-02 |
KR20190068567A (en) | 2019-06-18 |
JOP20190081A1 (en) | 2019-04-11 |
CN109789145A (en) | 2019-05-21 |
RU2019113756A (en) | 2020-11-13 |
TW201817424A (en) | 2018-05-16 |
WO2018069843A9 (en) | 2018-08-02 |
AU2017342207B2 (en) | 2020-01-30 |
US10722518B2 (en) | 2020-07-28 |
CA3035852A1 (en) | 2018-04-19 |
MX2019004342A (en) | 2019-07-01 |
PH12019500464A1 (en) | 2019-11-25 |
JP2019534885A (en) | 2019-12-05 |
US20180125853A1 (en) | 2018-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
SG11201806383TA (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen | |
SG11201806620TA (en) | Compositions and methods for treating infections | |
SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration | |
SG11201811022TA (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
SG11201908870PA (en) | Methods of preventing or treating ophthalmic diseases |